[{"id":"accc8beb-5a40-4334-a4ae-f00e0d7cc772","acronym":"ELEVATE","url":"https://clinicaltrials.gov/study/NCT05563220","created_at":"2022-10-03T15:56:32.608Z","updated_at":"2025-02-25T14:17:18.649Z","phase":"Phase 1/2","brief_title":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT05563220 - ELEVATE","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" HER-2 • ER • PIK3CA • CDK4","pipe":" | ","alterations":" PIK3CA mutation","tags":["HER-2 • ER • PIK3CA • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • Truqap (capivasertib) • Orserdu (elacestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 01/24/2023","start_date":" 01/24/2023","primary_txt":" Primary completion: 12/27/2026","primary_completion_date":" 12/27/2026","study_txt":" Completion: 12/28/2028","study_completion_date":" 12/28/2028","last_update_posted":"2025-02-18"},{"id":"757c7ea9-28ea-4973-bbc9-a09748839d13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039801","created_at":"2021-09-10T16:57:15.373Z","updated_at":"2025-02-25T15:35:16.395Z","phase":"Phase 1","brief_title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05039801","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2","pipe":" | ","alterations":" PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Truqap (capivasertib) • IPN60090"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/09/2021","start_date":" 09/09/2021","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-10"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"bbd54b62-457a-494d-90d2-1614ae83c172","acronym":"DESTINY-Breast08","url":"https://clinicaltrials.gov/study/NCT04556773","created_at":"2021-01-18T21:46:53.987Z","updated_at":"2025-02-25T16:45:09.442Z","phase":"Phase 1","brief_title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT04556773 - DESTINY-Breast08","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/17/2020","start_date":" 12/17/2020","primary_txt":" Primary completion: 08/16/2023","primary_completion_date":" 08/16/2023","study_txt":" Completion: 12/04/2025","study_completion_date":" 12/04/2025","last_update_posted":"2025-02-05"},{"id":"f4599b74-514d-415f-a4c1-0ad32a88ef07","acronym":"A071401","url":"https://clinicaltrials.gov/study/NCT02523014","created_at":"2021-01-18T12:11:52.655Z","updated_at":"2025-02-25T13:11:46.229Z","phase":"Phase 2","brief_title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas","source_id_and_acronym":"NCT02523014 - A071401","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation","tags":["PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-01-15"},{"id":"8cb4234f-c738-4083-b46f-8fc3430135ea","acronym":"ComPAKT","url":"https://clinicaltrials.gov/study/NCT02338622","created_at":"2021-01-17T17:26:12.811Z","updated_at":"2025-02-25T15:06:26.078Z","phase":"Phase 1","brief_title":"Trial of Olaparib in Combination with AZD5363 (ComPAKT)","source_id_and_acronym":"NCT02338622 - ComPAKT","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" BRCA1 • BRCA2 • PARP1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • PARP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Truqap (capivasertib)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 03/31/2014","start_date":" 03/31/2014","primary_txt":" Primary completion: 03/21/2016","primary_completion_date":" 03/21/2016","study_txt":" Completion: 03/21/2017","study_completion_date":" 03/21/2017","last_update_posted":"2024-09-26"},{"id":"ae9e478e-e6fe-4a4a-997a-f85a6be1d091","acronym":"","url":"https://clinicaltrials.gov/study/NCT03801369","created_at":"2021-01-18T18:47:29.710Z","updated_at":"2025-02-25T15:08:15.103Z","phase":"Phase 2","brief_title":"Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03801369","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" HER-2 • ER • PGR • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["HER-2 • ER • PGR • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • Truqap (capivasertib) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-08-13"},{"id":"7b8dfa1c-2da2-4d1b-8945-ea6ec1ea6662","acronym":"","url":"https://clinicaltrials.gov/study/NCT05720260","created_at":"2023-02-09T15:00:11.511Z","updated_at":"2024-07-02T16:34:27.630Z","phase":"Phase 2","brief_title":"Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC","source_id_and_acronym":"NCT05720260","lead_sponsor":"National Taiwan University Hospital","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • fulvestrant • Truqap (capivasertib) • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 01/17/2023","start_date":" 01/17/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-10"},{"id":"b5216033-99a5-4f51-828d-87fa62fb0d17","acronym":"CAPItello-292","url":"https://clinicaltrials.gov/study/NCT04862663","created_at":"2021-04-28T13:53:54.000Z","updated_at":"2024-07-02T16:34:37.553Z","phase":"Phase 3","brief_title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","source_id_and_acronym":"NCT04862663 - CAPItello-292","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • Truqap (capivasertib)"],"overall_status":"Recruiting","enrollment":" Enrollment 895","initiation":"Initiation: 05/10/2021","start_date":" 05/10/2021","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 08/14/2029","study_completion_date":" 08/14/2029","last_update_posted":"2024-06-06"},{"id":"1315f5e9-3b04-4aab-a843-bdf4b3d84f6e","acronym":"SNARE","url":"https://clinicaltrials.gov/study/NCT05593497","created_at":"2022-10-25T13:56:29.819Z","updated_at":"2024-07-02T16:34:59.265Z","phase":"Phase 2","brief_title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","source_id_and_acronym":"NCT05593497 - SNARE","lead_sponsor":"VA Office of Research and Development","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • Truqap (capivasertib) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-06-04"},{"id":"84a680b4-a96a-45c2-825f-d8e10004766e","acronym":"BEGONIA","url":"https://clinicaltrials.gov/study/NCT03742102","created_at":"2021-01-18T18:19:46.394Z","updated_at":"2024-07-02T16:35:02.191Z","phase":"Phase 1/2","brief_title":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03742102 - BEGONIA","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression • PD-L1 expression + HER-2 overexpression","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression • PD-L1 expression + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Truqap (capivasertib) • Datroway (datopotamab deruxtecan-dlnk) • oleclumab (MEDI9447)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 11/14/2024","primary_completion_date":" 11/14/2024","study_txt":" Completion: 11/14/2024","study_completion_date":" 11/14/2024","last_update_posted":"2024-05-21"},{"id":"bd3903e4-47f8-44a5-a2e7-496b069f8567","acronym":"","url":"https://clinicaltrials.gov/study/NCT02208375","created_at":"2021-01-18T10:20:36.481Z","updated_at":"2024-07-02T16:35:02.701Z","phase":"Phase 1/2","brief_title":"mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian","source_id_and_acronym":"NCT02208375","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR • BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["ER • PGR • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 11/11/2014","start_date":" 11/11/2014","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-05-17"},{"id":"b3ec16de-b06c-4b4e-97bd-502739a6230d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02664935","created_at":"2021-01-18T12:59:26.753Z","updated_at":"2025-02-25T14:36:10.262Z","phase":"Phase 2","brief_title":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02664935","lead_sponsor":"University of Birmingham","biomarkers":" NKX2-1 • TP63","pipe":"","alterations":" ","tags":["NKX2-1 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tagrisso (osimertinib) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Koselugo (selumetinib) • Truqap (capivasertib) • fexagratinib (ABSK091) • ceralasertib (AZD6738) • sitravatinib (MGCD516) • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 423","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-13"},{"id":"b32f23eb-9a26-4345-b81c-19e88cc236d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01226316","created_at":"2021-01-18T04:55:40.912Z","updated_at":"2024-07-02T16:35:04.747Z","phase":"Phase 1","brief_title":"Safety, Tolerability \u0026 Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules","source_id_and_acronym":"NCT01226316","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PIK3CA • PTEN","pipe":" | ","alterations":" ER positive • PIK3CA mutation • PTEN mutation • AKT1 mutation","tags":["HER-2 • ER • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation • PTEN mutation • AKT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Truqap (capivasertib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 285","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 04/26/2019","primary_completion_date":" 04/26/2019","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-09"},{"id":"8a99bf6d-058b-4af4-b00a-38329fd93bc8","acronym":"EAY131-Y","url":"https://clinicaltrials.gov/study/NCT04439123","created_at":"2021-01-18T21:22:05.308Z","updated_at":"2024-07-02T16:35:05.058Z","phase":"Phase 2","brief_title":"Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)","source_id_and_acronym":"NCT04439123 - EAY131-Y","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truqap (capivasertib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/31/2016","start_date":" 05/31/2016","primary_txt":" Primary completion: 11/08/2019","primary_completion_date":" 11/08/2019","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-05-08"},{"id":"d69f4d60-888a-44f8-a2da-88505cf7f180","acronym":"CAPItello-281","url":"https://clinicaltrials.gov/study/NCT04493853","created_at":"2021-01-18T21:35:12.569Z","updated_at":"2024-07-02T16:35:07.673Z","phase":"Phase 3","brief_title":"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency","source_id_and_acronym":"NCT04493853 - CAPItello-281","lead_sponsor":"AstraZeneca","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • Truqap (capivasertib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1012","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 10/04/2024","primary_completion_date":" 10/04/2024","study_txt":" Completion: 03/26/2027","study_completion_date":" 03/26/2027","last_update_posted":"2024-04-25"},{"id":"0066169f-eea4-4ffc-bdc0-531deb0491dd","acronym":"CAPITAL","url":"https://clinicaltrials.gov/study/NCT05008055","created_at":"2021-08-17T14:53:09.224Z","updated_at":"2024-07-02T16:35:14.322Z","phase":"Phase 2","brief_title":"Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05008055 - CAPITAL","lead_sponsor":"AstraZeneca","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truqap (capivasertib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/03/2021","start_date":" 11/03/2021","primary_txt":" Primary completion: 08/22/2023","primary_completion_date":" 08/22/2023","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-18"},{"id":"35555a3a-c45f-4001-9f3f-587dd24c1ab1","acronym":"SERENA-1","url":"https://clinicaltrials.gov/study/NCT03616587","created_at":"2021-01-17T17:55:38.542Z","updated_at":"2024-07-02T16:35:16.432Z","phase":"Phase 1","brief_title":"Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.","source_id_and_acronym":"NCT03616587 - SERENA-1","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • Truqap (capivasertib) • anastrozole • camizestrant (AZD9833)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 396","initiation":"Initiation: 10/11/2018","start_date":" 10/11/2018","primary_txt":" Primary completion: 07/10/2024","primary_completion_date":" 07/10/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-03-05"},{"id":"56cf2aa4-0bb8-4ec7-a2a3-ea438f302a37","acronym":"CAPItello-291","url":"https://clinicaltrials.gov/study/NCT04305496","created_at":"2021-01-18T20:52:48.632Z","updated_at":"2024-07-02T16:35:47.030Z","phase":"Phase 3","brief_title":"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT04305496 - CAPItello-291","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PIK3CA • PGR • PTEN • AKT1","pipe":" | ","alterations":" HER-2 negative • PGR expression","tags":["HER-2 • ER • PIK3CA • PGR • PTEN • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Truqap (capivasertib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 08/15/2022","primary_completion_date":" 08/15/2022","study_txt":" Completion: 06/07/2024","study_completion_date":" 06/07/2024","last_update_posted":"2023-05-29"},{"id":"0b31801d-bfeb-43b6-a0a2-863055f3325d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03310541","created_at":"2021-01-19T14:57:57.429Z","updated_at":"2024-07-02T16:35:48.874Z","phase":"Phase 1","brief_title":"AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations","source_id_and_acronym":"NCT03310541","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" AKT2","pipe":" | ","alterations":" AKT3 mutation","tags":["AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AKT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • Truqap (capivasertib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/11/2017","start_date":" 10/11/2017","primary_txt":" Primary completion: 05/03/2023","primary_completion_date":" 05/03/2023","study_txt":" Completion: 05/03/2023","study_completion_date":" 05/03/2023","last_update_posted":"2023-05-05"},{"id":"c9a26a8f-82cd-4a91-80ba-4efe0233fbf4","acronym":"BEECH","url":"https://clinicaltrials.gov/study/NCT01625286","created_at":"2021-01-17T18:03:11.291Z","updated_at":"2024-07-02T16:35:57.458Z","phase":"Phase 1/2","brief_title":"Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients","source_id_and_acronym":"NCT01625286 - BEECH","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Truqap (capivasertib)"],"overall_status":"Completed","enrollment":" Enrollment 148","initiation":"Initiation: 10/03/2012","start_date":" 10/03/2012","primary_txt":" Primary completion: 01/28/2017","primary_completion_date":" 01/28/2017","study_txt":" Completion: 10/03/2022","study_completion_date":" 10/03/2022","last_update_posted":"2023-01-18"},{"id":"378567fb-8a7c-4f5f-a289-d866a78d5f0f","acronym":"FAKTION","url":"https://clinicaltrials.gov/study/NCT01992952","created_at":"2021-01-18T09:05:30.071Z","updated_at":"2025-02-25T15:05:46.817Z","phase":"Phase 1b/2","brief_title":"Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer","source_id_and_acronym":"NCT01992952 - FAKTION","lead_sponsor":"Velindre NHS Trust","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Truqap (capivasertib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 149","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-08-10"},{"id":"fac4bd62-7009-4c63-9d58-007fc498b1b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02451956","created_at":"2021-01-18T11:45:26.832Z","updated_at":"2024-07-02T16:36:52.012Z","phase":"Phase 2","brief_title":"Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy","source_id_and_acronym":"NCT02451956","lead_sponsor":"Samsung Medical Center","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation • PIK3CA amplification","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PIK3CA amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Truqap (capivasertib)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 01/07/2015","start_date":" 01/07/2015","primary_txt":" Primary completion: 05/24/2019","primary_completion_date":" 05/24/2019","study_txt":" Completion: 05/24/2019","study_completion_date":" 05/24/2019","last_update_posted":"2019-12-30"},{"id":"a7cf27e8-0f88-42d3-a315-132a41f8e17d","acronym":"plasmaMATCH","url":"https://clinicaltrials.gov/study/NCT03182634","created_at":"2021-01-17T17:26:44.253Z","updated_at":"2024-07-02T16:37:03.635Z","phase":"Phase 2a","brief_title":"The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial","source_id_and_acronym":"NCT03182634 - plasmaMATCH","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" ER","pipe":" | ","alterations":" HER-2 positive • ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Nerlynx (neratinib) • fulvestrant • Truqap (capivasertib) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 1150","initiation":"Initiation: 12/15/2016","start_date":" 12/15/2016","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2019-01-22"}]